CoChat

Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells

Open access
Klubo-Gwiezdzinska, Joanna, Jensen, Kirk, Costello, John, Patel, Aneeta, Hoperia, Victoria, Bauer, Andrew, Burman, Kenneth D, Wartofsky, Leonard, Vasko, Vasyl · 2012 · Endocrine-Related Cancer
Cited by 87

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Medullary thyroid cancer (MTC) is associated with activation of mammalian target of rapamycin (mTOR) signaling pathways. Recent studies showed that the antidiabetic agent metformin decreases proliferation of cancer cells through 5′-AMP-activated protein kinase (AMPK)-dependent inhibition of mTOR. In the current study, we assessed the effect of metformin on MTC cells. For this purpose, we determined growth, viability, migration, and resistance to anoikis assays using two MTC-derived cell lines (TT and MZ-CRC-1). Expressions of molecular targets of metformin were examined in MTC cell lines and in 14 human MTC tissue samples. We found that metformin inhibited growth and decreased expression of cyclin D1 in MTC cells. Treatment with metformin was associated with inhibition of mTOR/p70S6K/pS6 signaling and downregulation of pERK in both TT and MZ-CRC-1 cells. Metformin had no significant effects on pAKT in the cell lines examined. Metformin-inducible AMPK activation was noted only in TT cells. Treatment with AMPK inhibitor (compound C) or AMPK silencing did not prevent growth inhibitory effects of metformin in TT cells. Metformin had no effect on MTC cell migration but reduced the ability of cells to form multicellular spheroids in nonadherent conditions. Immunostaining of human MTC showed over-expression of cyclin D1 in all tumors compared with corresponding normal tissue. Activation of mTOR/p70S6K was detected in 8/14 (57.1%) examined tumors. Together, these findings indicate that growth inhibitory effects in MTC cells are associated with downregulation of both mTOR/6SK and pERK signaling pathways. Expression of metformin's molecular targets in human MTC cells suggests its potential utility for the treatment of MTC in patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/erc-12-0046

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 87

Metadata

Authors
Klubo-Gwiezdzinska, J., Jensen, K., Costello, J., Patel, A., Hoperia, V., Bauer, A., Burman, K. D., Wartofsky, L., & Vasko, V.
Venue
Endocrine-Related Cancer
Published
2012-03-02
Volume
19
Issue
3
Pages
447-456
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2102192525
Cited by
87
References
8
FWCI
3.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. https://app.cochat.ai/papers/10.1530/erc-12-0046
The paper
Klubo-Gwiezdzinska, J., Jensen, K., Costello, J., Patel, A., Hoperia, V., Bauer, A., Burman, K. D., Wartofsky, L., & Vasko, V. (2012). Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocrine-Related Cancer. https://doi.org/10.1530/erc-12-0046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.